Evaluation of Preventive Effect of tofogliflozin on cardiovascular function in type 2 diabetes with cardiovascular diseases

Evaluation of Preventive Effect of tofogliflozin on cardiovascular function in type 2 diabetes with cardiovascular diseases - tofogliflozin study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018344

Enrollment

Registered

2015-09-01

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes with cardiovascular disease

Interventions

tofogliflozin 20 mg / day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) HbA1c level is higher than 7.0% 2) Patients with ischemic heart disease, valbular disease, cardiacmyopathy, or hypertensive heart disease

Exclusion criteria

Exclusion criteria: 1) BMI < 18.0 2) history of cerebral infarction 3) patients whose dose of diuretics are changed within 3 months 4) estimated GFR < 45 ml/min 5) patients inplanted pacemaker 6) patients with pregnancy and lactation 7) patiets enrolled other clinical trial

Design outcomes

Primary

Measure	Time frame
BNP, marker of cardiac echography after 6 months	—

Countries

Japan

Contacts

Public ContactHisashi Makino

National Cerbral and Cardiovascular Center Atherosclerosis and Diabetes

makinoh@hsp.ncvc.go.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026